Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03434379 · OUTCOME

Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma · Source last updated 2023-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
micrograms/milliliter (mcg/mL)
Interval / dispersion
Standard Deviation
Time frame
Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)

Analysis population: The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.

Groups in this outcome

Atezolizumab + Bevacizumab - Global

Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab + Bevacizumab - Global309

Reported measurements

Source class 1
Values in micrograms/milliliter (mcg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Atezolizumab + Bevacizumab - Global398132Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        132
        value
        398
denoms
  1. counts
    1. group Id
      OG000
      value
      309
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    id
    OG000
    title
    Atezolizumab + Bevacizumab - Global
param Type
MEAN
population Description
The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.
reporting Status
POSTED
time Frame
Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)
title
Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population
type
SECONDARY
unit Of Measure
micrograms/milliliter (mcg/mL)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice